Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Stan Kurowski"'
Autor:
Mihirbaran Mandal, Maria Madeira, Rupesh P. Amin, Alexei V. Buevich, Alan Cheng, Marc Labroli, Xiaoxiang Liu, John Acton, Barbara Pio, Andrea Basso, Harry Chobanian, Grace Dong, Jamie Dropinski, Yan Guo, Zhuyan Guo, Stan Kurowski, Walter Korfmacher, Sandra Lee, Dongfang Meng, Debra Ondeyka, Zhiqiang Yang, Rumin Zhang, Huijun Wei, Zhicai Wu, Fengqi Zhang, Gordon Wollenberg, Tesfaye Biftu, William J. Greenlee, Madhu Chintala, Milana Maletic, Zhaoning Zhu
Publikováno v:
Journal of Medicinal Chemistry. 65:5575-5592
Vorapaxar is an approved drug for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or with peripheral arterial disease. Subsequent to the discovery of Vorapaxar, medicinal chemistry efforts were co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20d0e58362d38a85e8d5aef1a3cbe66a
https://doi.org/10.1021/acs.jmedchem.1c02048
https://doi.org/10.1021/acs.jmedchem.1c02048
Autor:
Xinkang Wang, Dietmar Seiffert, Kenneth P. Ellsworth, Mark D. Erion, Xueping Zhou, Patrick Andre, Amjad Ali, Gino Castriota, Scott D. Edmondson, Stan Kurowski, David E. Gutstein, Zhu Chen, Donald Chu, Weizhen Wu, Lin Chu
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 360:476-483
Factor XI (FXI) is an integral component of the intrinsic pathway of the coagulation cascade and plays a critical role in thrombus formation. Because its role in the pathogenesis of cerebral microembolic signals (MES) is unclear, this study used a po
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8bb6f4efc77b882cdf123fcb2b15ca6a
https://doi.org/10.1124/jpet.116.238600
https://doi.org/10.1124/jpet.116.238600
Autor:
Keith Eagen, Yunsheng Hsieh, Mariappan V. Chelliah, Stan Kurowski, Zhuyan Guo, Madhu Chintala, William J. Greenlee, Hsingan Tsai, Samuel Chackalamannil, Ho-Sam Ahn, Yan Xia, George Boykow
Publikováno v:
ACS Medicinal Chemistry Letters. 5:561-565
We have synthesized several C7-spirocyclic analogues of vorapaxar and evaluated their in vitro activities against PAR-1 receptor. Some of these analogues showed activities and rat plasma levels comparable to vorapaxar. Compound 5c from this series sh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5167ac4b35159c9670df81e0eaf948e6
https://doi.org/10.1021/ml500008w
https://doi.org/10.1021/ml500008w
Autor:
Stan Kurowski, Mariappan V. Chelliah, William J. Greenlee, Madhu Chintala, Yunsheng Hsieh, Yan Xia, George Boykow, Ho-Sam Ahn, Samuel Chackalamannil
Publikováno v:
ACS Medicinal Chemistry Letters. 5:183-187
We have synthesized several C7-aminomethyl analogues of vorapaxar that are potent PAR-1 antagonists. Many of these analogues showed excellent in vitro binding affinity and pharmacokinetics profile in rats. Compound 6a from this series showed excellen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64b51fb9c036df9fa0fa9ec39ff0de40
https://doi.org/10.1021/ml400452v
https://doi.org/10.1021/ml400452v
Autor:
Anandan Palani, Ashwin U. Rao, Xiao Chen, Xianhai Huang, Jing Su, Haiqun Tang, Ying Huang, Jun Qin, Dong Xiao, Sylvia Degrado, Michael Sofolarides, Xiaohong Zhu, Zhidan Liu, Brian McKittrick, Wei Zhou, Robert Aslanian, William J. Greenlee, Mary Senior, Boonlert Cheewatrakoolpong, Hongtao Zhang, Constance Farley, John Cook, Stan Kurowski, Qiu Li, Margaret van Heek, Gangfeng Wang, Yunsheng Hsieh, Fangbiao Li, Scott Greenfeder, Madhu Chintala
Publikováno v:
ACS Medicinal Chemistry Letters. 3:63-68
Structure-guided optimization of a series of C-5 alkyl substituents led to the discovery of a potent nicotinic acid receptor agonist SCH 900271 (33) with an EC50 of 2 nM in the hu-GPR109a assay. Compound 33 demonstrated good oral bioavailability in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54c5c0846188e03944198c603168e99c
https://doi.org/10.1021/ml200243g
https://doi.org/10.1021/ml200243g
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 30:2143-2149
Objective— To determine the antithrombotic effects of SCH 602539, an analog of the selective protease-activated receptor (PAR)-1 antagonist vorapaxar (formerly SCH 530348) currently in advanced clinical development, and the P2Y 12 ADP receptor anta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f648d95fc7b532030bf047a13f28ee0e
https://doi.org/10.1161/atvbaha.110.203414
https://doi.org/10.1161/atvbaha.110.203414
Publikováno v:
British Journal of Pharmacology. 134:1705-1710
1. Melanotan-II had been reported to cause penile erections in men with erectile dysfunction. In the present study, we investigated the mechanisms by which systemic administration of MT-II increases intracavernosal pressure in anaesthetized rabbits.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b452079ac0f2086460f48fc0fb0c04fd
https://doi.org/10.1038/sj.bjp.0704437
https://doi.org/10.1038/sj.bjp.0704437
Autor:
Subbarao Vemulapalli, Stan Kurowski
Publikováno v:
Fundamental and Clinical Pharmacology. 15:1-7
The contribution of NO-cGMP dependent pathway to phentolamine mesylate-evoked nonadrenergic, noncholinergic relaxation of rabbit corpus cavernosum was investigated in vitro. Stimulation of nonadrenergic, noncholinergic neurons of the rabbit corpus ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a7adb7c57bc4bb48839c32c2742537a5
https://doi.org/10.1046/j.1472-8206.2001.00010.x
https://doi.org/10.1046/j.1472-8206.2001.00010.x
Autor:
Arthur Brown, Peter J.S. Chiu, Edmund J. Sybertz, Kerry Griscti, Subbarao Vemulapalli, Stan Kurowski
Publikováno v:
European Journal of Pharmacology. 257:95-102
The role of phosphoramidon-sensitive endothelin converting enzyme in the release of endogenous endothelin-1 was investigated in anesthetized rats. Intravenous infusion of phosphoramidon 0.3 mg/kg/min did not suppress the release of endothelin-1 stimu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a1f4d08b28411e8a282463281d5aa63
https://doi.org/10.1016/0014-2999(94)90699-8
https://doi.org/10.1016/0014-2999(94)90699-8
Autor:
Xianhai Huang, Anandan Palani, John Cook, Stan Kurowski, Constance Farley, Jun Qin, Madhu Chintala, Xiaohong Zhu, Margaret van Heek, Ying Huang, Hongtao Zhang, Boonlert Cheewatrakoolpong, Sylvia J. Degrado, Ashwin U. Rao, Scott Greenfeder, Fangbiao Li, Qiu Li, Dong Xiao, Xiao Chen, Ganfeng Wang, Yunsheng Hsieh, Zhidan Liu, Robert G. Aslanian
Nicotinic acid has been used clinically for decades to control serum lipoproteins. Nicotinic acid lowers very low-density lipoprotein (VLDL)-cholesterol, low-density lipoprotein (LDL)-cholesterol, and lipoprotein-a (LPa), and it is also effective in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ed5966656f2ea3f783fe9ed9e9ab050
https://europepmc.org/articles/PMC4017979/
https://europepmc.org/articles/PMC4017979/
